Myostatin and sarcopenia: Opportunities and challenges - A mini-review

Gerontology

Volumn 60, Issue 4, 2014, Pages 289-293

  White, Thomas A ^a   Lebrasseur, Nathan K ^a,b  

^a MAYO CLINIC   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

Author keywords

Aging; Atrophy; Diabetes; Drug discovery; Frailty; Growth and differentiation factor; Obesity; Skeletal muscle

Indexed keywords

MYOSTATIN; MSTN PROTEIN, HUMAN;

AGING; COMORBIDITY; DIABETES MELLITUS; DISEASE COURSE; HEART FAILURE; HUMAN; MUSCLE FUNCTION; MUSCLE GROWTH; MUSCLE MASS; MUSCLE STRENGTH; NEOPLASM; NONHUMAN; PHYSICAL INACTIVITY; PHYSICAL PERFORMANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; QUALITY OF LIFE; REVIEW; SARCOPENIA; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; LONG TERM CARE; SHORT COURSE THERAPY; AGED; ANIMAL; ANTAGONISTS AND INHIBITORS; MOUSE; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

AGED; AGING; ANIMALS; HUMANS; MICE; MUSCLE, SKELETAL; MYOSTATIN; SARCOPENIA; SIGNAL TRANSDUCTION;

EID: 84903520673     PISSN: 0304324X     EISSN: 14230003     Source Type: Journal    
DOI: 10.1159/000356740     Document Type: Review

References (32)

1. McPherron AC, Lawler AM, Lee SJ: Regulation of skeletal muscle mass in mice by a new TGF-β superfamily member. Nature 1997; 387: 83-90.
2. Sharma M, Kambadur R, Matthews KG, Somers WG, Devlin GP, Conaglen JV, Fowke PJ, Bass JJ: Myostatin, a transforming growth factor-β superfamily member, is expressed in heart muscle and is upregulated in cardiomyocytes after infarct. J Cell Physiol 1999; 180: 1-9.
3. Langley B, Thomas M, Bishop A, Sharma M, Gilmour S, Kambadur R: Myostatin inhibits myoblast differentiation by down-regulating MyoD expression. J Biol Chem 2002; 277: 49831-49840.
4. Yang W, Zhang Y, Li Y, Wu Z, Zhu D: Myostatin induces cyclin D1 degradation to cause cell cycle arrest through a phosphatidylinositol 3-kinase/AKT/GSK-3β pathway and is antagonized by insulin-like growth factor 1. J Biol Chem 2007; 282: 3799-3808.
5. Sartori R, Milan G, Patron M, Mammucari C, Blaauw B, Abraham R, Sandri M: Smad2 and 3 transcription factors control muscle mass in adulthood. Am J Physiol Cell Physiol 2009; 296:C1248-C1257.
6. Trendelenburg AU, Meyer A, Rohner D, Boyle J, Hatakeyama S, Glass DJ: Myostatin reduces Akt/TORC1/p70S6K signaling, inhibiting myoblast differentiation and myotube size. Am J Physiol Cell Physiol 2009; 296:C1258-C1270.
7. Schuelke M, Wagner KR, Stolz LE, Hubner C, Riebel T, Komen W, Braun T, Tobin JF, Lee SJ: Myostatin mutation associated with gross muscle hypertrophy in a child. N Engl J Med 2004; 350: 2682-2688.
8. Yarasheski KE, Bhasin S, Sinha-Hikim I, Pak-Loduca J, Gonzalez-Cadavid NF: Serum myostatin-immunoreactive protein is increased in 60-to 92-year-old women and men with muscle wasting. J Nutr Health Aging 2002; 6: 343-348.
9. Welle S, Bhatt K, Shah B, Thornton C: Insulin-like growth factor-1 and myostatin MRNA expression in muscle: comparison between 62-77 and 21-31 year old men. Exp Gerontol 2002; 37: 833-839.
10. Ratkevicius A, Joyson A, Selmer I, Dhanani T, Grierson C, Tommasi AM, DeVries A, Rauchhaus P, Crowther D, Alesci S, Yaworsky P, Gilbert F, Redpath TW, Brady J, Fearon KC, Reid DM, Greig CA, Wackerhage H: Serum concentrations of myostatin and myostatininteracting proteins do not differ between young and sarcopenic elderly men. J Gerontol A Biol Sci Med Sci 2011; 66: 620-626.
11. Lee SJ, McPherron AC: Regulation of myostatin activity and muscle growth. Proc Natl Acad Sci USA 2001; 98: 9306-9311.
12. Wolfman NM, McPherron AC, Pappano WN, Davies MV, Song K, Tomkinson KN, Wright JF, Zhao L, Sebald SM, Greenspan DS, Lee SJ: Activation of latent myostatin by the BMP-1/tolloid family of metalloproteinases. Proc Natl Acad Sci USA 2003; 100: 15842-15846.
13. Lee SJ: Regulation of muscle mass by myostatin. Annu Rev Cell Dev Biol 2004; 20: 61-86.
14. Fakhouri TH, Ogden CL, Carroll MD, Kit BK, Flegal KM: Prevalence of obesity among older adults in the United States, 2007-2010. NCHS Data Brief 2012, pp 1-8.
15. Seeman TE, Merkin SS, Crimmins EM, Karlamangla AS: Disability trends among older Americans: national health and nutrition examination surveys, 1988-1994 and 1999-2004. Am J Public Health 2010; 100: 100-107.
16. Allen DL, Hittel DS, McPherron AC: Expression and function of myostatin in obesity, diabetes, and exercise adaptation. Med Sci Sports Exerc 2011; 43: 1828-1835.
17. Lebrasseur NK: Building muscle, browning fat and preventing obesity by inhibiting myostatin. Diabetologia 2012; 55: 13-17.
18. Hittel DS, Berggren JR, Shearer J, Boyle K, Houmard JA: Increased secretion and expression of myostatin in skeletal muscle from extremely obese women. Diabetes 2009; 58: 30-38.
19. Milan G, Dalla Nora E, Pilon C, Pagano C, Granzotto M, Manco M, Mingrone G, Vettor R: Changes in muscle myostatin expression in obese subjects after weight loss. J Clin Endocrinol Metab 2004; 89: 2724-2727.
20. Park JJ, Berggren JR, Hulver MW, Houmard JA, Hoffman EP: GRB14, GPD1, and GDF8 as potential network collaborators in weight loss-induced improvements in insulin action in human skeletal muscle. Physiol Genomics 2006; 27: 114-121.
21. Akpan I, Goncalves MD, Dhir R, Yin X, Pistilli EE, Bogdanovich S, Khurana TS, Ucran J, Lachey J, Ahima RS: The effects of a soluble activin type IIB receptor on obesity and insulin sensitivity. Int J Obes (Lond) 2009; 33: 1265-1273.
22. Bernardo BL, Wachtmann TS, Cosgrove PG, Kuhn M, Opsahl AC, Judkins KM, Freeman TB, Hadcock JR, LeBrasseur NK: Postnatal PPAR? activation and myostatin inhibition exert distinct yet complimentary effects on the metabolic profile of obese insulin-resistant mice. PLoS One 2010; 5:e11307.
23. LeBrasseur NK, Walsh K, Arany Z: Metabolic benefits of resistance training and fast glycolytic skeletal muscle. Am J Physiol Endocrinol Metab 2011; 300:E3-E10.
24. Whittemore LA, Song K, Li X, Aghajanian J, Davies M, Girgenrath S, Hill JJ, Jalenak M, Kelley P, Knight A, Maylor R, O'Hara D, Pearson A, Quazi A, Ryerson S, Tan XY, Tomkinson KN, Veldman GM, Widom A, Wright JF, Wudyka S, Zhao L, Wolfman NM: Inhibition of myostatin in adult mice increases skeletal muscle mass and strength. Biochem Biophys Res Commun 2003; 300: 965-971.
25. LeBrasseur NK, Schelhorn TM, Bernardo BL, Cosgrove PG, Loria PM, Brown TA: Myostatin inhibition enhances the effects of exercise on performance and metabolic outcomes in aged mice. J Gerontol A Biol Sci Med Sci 2009; 64: 940-948.
26. Attie KM, Borgstein NG, Yang Y, Condon CH, Wilson DM, Pearsall AE, Kumar R, Willins DA, Seehra JS, Sherman ML: A single ascending-dose study of muscle regulator ACE-031 in healthy volunteers. Muscle Nerve 2013; 47: 416-423.
27. Morissette MR, Stricker JC, Rosenberg MA, Buranasombati C, Levitan EB, Mittleman MA, Rosenzweig A: Effects of myostatin deletion in aging mice. Aging Cell 2009; 8: 573-583.
28. Wilkes JJ, Lloyd DJ, Gekakis N: Loss-of-function mutation in myostatin reduces tumor necrosis factor-β production and protects liver against obesity-induced insulin resistance. Diabetes 2009; 58: 1133-1143.
29. Tu P, Bhasin S, Hruz PW, Herbst KL, Castellani LW, Hua N, Hamilton JA, Guo W: Genetic disruption of myostatin reduces the development of proatherogenic dyslipidemia and atherogenic lesions in Ldlr null mice. Diabetes 2009; 58: 1739-1748.
30. Mosher DS, Quignon P, Bustamante CD, Sutter NB, Mellersh CS, Parker HG, Ostrander EA: A mutation in the myostatin gene increases muscle mass and enhances racing performance in heterozygote dogs. PLoS Genet 2007; 3:e79.
31. Lee SJ: Quadrupling muscle mass in mice by targeting TGF-β signaling pathways. PLoS One 2007; 2:e789.
32. McPherron AC, Lee SJ: Suppression of body fat accumulation in myostatin-deficient mice. J Clin Invest 2002; 109: 595-601.